ACTI — Active Biotech AB publ Share News
0.000.00%
Last trade - 00:00- SEK207.73m
- SEK163.93m
Brief: Active Biotech Provides Update On Laquinimod In Huntington's Disease
Active Biotech: Slumps by a third after key trial update
Brief: Active Biotech gives update on laquinimod in Huntington's disease
Brief: Active Biotech Q1 operating loss narrows
Brief: Active Biotech says rights issue oversubscribed
Brief: Active Biotech AB Q4 Net Sales Down At SEK 5.4 Million
Brief: Active Biotech carries out 48 mln SEK rights issue
Brief: Active Biotech receives waiver from bank commitment, expires on Feb 27
Brief: Active Biotech provides updated information about company's financial situation
Brief: Active Biotech Announce Results In Arpeggio Phase II Trial With Laquinimod In Primary Progressive MS
Brief: Active Biotech Q2 operating loss 23.1 mln SEK
Brief: Active Biotech appoints Helen Tuvesson as new CEO
Brief: Active Biotech says CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint
Brief: Teva and Active Biotech announce CONCERTO trial of Laquinimod in RRMS did not meet primary endpoint
Brief: Active Biotech: FDA grants Orphan Drug Designation for tasquinimod for multiple myeloma treatment
Brief: Active Biotech Q4 operating loss narrows to SEK 13.5 mln
Brief: Active Biotech says receives European patent for tasquinimod
Brief: Active Biotech raises 55 mln SEK before costs in rights issue
Brief: Active Biotech to raise SEK 55 mln via rights issue